 |
 |
Date Announced: 03 Jan 2012
Laser system is indicated for treatment of severe angina.
TORONTO, ONTARIO and WAYNE, NEW JERSEY--(Marketwire - Jan. 3, 2012) - Novadaq® Technologies Inc. (TSX:NDQ), a developer of real-time imaging systems for use in the operating room, and MAQUET Cardiovascular, a leader in providing innovative products for cardiac surgery, vascular intervention and cardiac support, announced today that the companies have signed an agreement naming MAQUET Cardiovascular as the exclusive distributor of Novadaq's CO2 Heart Laser™ Systems and procedure kits in the United States (U.S.).
The CO2 Heart Laser System for Transmyocardial Revascularization (TMR) is indicated for use in patients suffering from severe angina that is not amenable to traditional medical or coronary revascularization therapies. During the TMR procedure, the CO2 Heart Laser creates small channels in the heart tissue which stimulate improvements in blood flow to regions of the heart.
"This distribution agreement with Novadaq for the CO2 Heart Laser fits well into MAQUET's current portfolio of cardiac surgery products and allows us to provide our customers additional therapies to meet their patients' needs," said Raoul Quintero, President, U.S. Sales and Service Organization, MAQUET Medical Systems. "Being able to strategically augment our product portfolio through distribution agreements such as these allows us to ensure we are constantly providing the most innovative technologies to the physicians and patients we serve."
"The alliance with MAQUET represents Novadaq's fourth commercial agreement with a market leader," added Dr. Arun Menawat, President and CEO, Novadaq. "We are excited that the CO2 Heart Laser will now be sold in the U.S. by the industry's largest specialized cardiac surgery sales force, and we look forward to continuing to support our customers' service requirements."
Source: Novadaq
E-mail: dmartin@novadaq.com
Web Site: www.novadaq.com
| © 2024 SPIE Europe |
|
